Cronograma de promoção Enliven Therapeutics, Inc.
Sobre a empresa
Enliven Therapeutics, Inc., биофармацевтическая компания клинической стадии, специализируется на открытии и разработке низкомолекулярных ингибиторов для помощи пациентам с раком. В число ее низкомолекулярных ингибиторов киназ входят ELVN-001, который проходит оценку в клиническом исследовании фазы 1 у взрослых с хроническим миелолейкозом; и ELVN-002, клиническое исследование фазы 1 было активировано для оценки людей с раком, содержащим аномальный ген HER2. Компания базируется в Боулдере, штат Колорадо.
Цена ао | 25.54 |
---|---|
P/BV | -15.12 |
EV/EBITDA | 0.205 |
EBITDA | -0.0241 |
P/E | 285.84 |
ISIN | US29337E1029 |
Число акций ао | 0.03555 млрд |
Сайт | https://www.enliventherapeutics.com |
Валюта | usd |
IPO date | 2020-03-12 |
Sector | Health Care |
Industry | Pharmaceuticals |
Валюта отчета | usd |
Alteração de preço por dia: | +0.2523% (27.75) |
---|---|
Alteração de preço por semana: | -0.6783% (28.01) |
Alteração de preço por mês: | +24.64% (22.32) |
Alteração de preço em 3 meses: | +17.09% (23.76) |
Mudança de preço em seis meses: | +57.44% (17.67) |
Mudança de preço por ano: | +112.04% (13.12) |
Mudança de preço em 3 anos: | +641.87% (3.75) |
Mudança de preço desde o início do ano: | +167.5% (10.4) |
|
Subestimação
|
Eficiência
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Obrigação
|
Impulso de crescimento
|
Instituições | Volume | Compartilhar, % |
---|---|---|
Orbimed Advisors LLC. | 8996213 | 21.88 |
5AM Venture Management, LLC | 5798475 | 14.1 |
FMR, LLC | 3163482 | 7.69 |
Citadel Advisors Llc | 2296210 | 5.58 |
VR Adviser, LLC | 2214142 | 5.39 |
RA Capital Management, L.P. | 2122465 | 5.16 |
Cormorant Asset Management, LP | 1936133 | 4.71 |
Fairmount Funds Management LLC | 1924938 | 4.68 |
COMMODORE CAPITAL LP | 1731365 | 4.21 |
Frazier Life Sciences Management, L.P. | 830983 | 2.02 |
ETF | Compartilhar, % | Rentabilidade para o ano, % | Dividendos, % |
---|---|---|---|
Range Cancer Therapeutics ETF | 2.57735 | 47.24446537918 | 0.11955 |
Avantis U.S. Equity ETF | 0.00064 | 32.224830464267 | 1.59151 |
Virtus LifeSci Biotech Clinical Trials ETF | 0.83452 | 63.040315712071 | 0.33 |
ProShares Ultra Nasdaq Biotechnology | 0.06805 | 51.697637072723 | 0.85651 |
Dimensional US Core Equity Market ETF | 0.00034 | 30.983243755928 | 1.40618 |
iShares ESG Aware MSCI USA Small-Cap ETF | 0.04985 | 33.616398243045 | 1.49366 |
Fidelity MSCI Health Care Index ETF | 0.00633 | 13.390080209527 | 1.46057 |
ProShares Hedge Replication ETF | 0.00469 | 5.9237999659878 | 1.47892 |
Humankind US Stock ETF | 0.00485 | 18.809430395549 | 1.99919 |
Invesco Nasdaq Biotechnology ETF | 0.10446 | 28.578975171685 | 0.8565 |
iShares U.S. Pharmaceuticals ETF | 0.25343 | 17.60673599431 | 1.97922 |
iShares Morningstar Small-Cap ETF | 0.01255 | 30.095066471445 | 1.60498 |
iShares Micro-Cap ETF | 0.2071 | 36.318555985322 | 1.54048 |
iShares Russell 2000 Growth ETF | 0.05699 | 38.042556988 | 0.6026 |
iShares Russell 3000 ETF | 0.00186 | 32.57283798366 | 1.43482 |
iShares Morningstar Small-Cap ETF | 0.01255 | 391.25300933451 | 1.60498 |
Nuveen ESG Small-Cap ETF | 0.0415 | 29.971671388102 | 1.41019 |
Direxion Daily Pharmaceutical & Medical Bull 3X Shares | 0.48093 | 86.715867158672 | 1.2989 |
Schwab U.S. Small-Cap ETF | 0.01489 | 34.281650071124 | 1.51433 |
Schwab U.S. Broad Market ETF | 0.00128 | 32.5 | 1.43354 |
SPDR Portfolio MSCI Global Stock Market ETF | 0.00095 | 23.600605143722 | 2.19607 |
ProShares UltraPro Russell2000 | 0.01762 | 89.821266282945 | 1.47873 |
Vanguard Russell 3000 ETF | 0 | 31.87314172448 | 1.43817 |
Vanguard Russell 2000 Growth ETF | 0.05 | 39.350070246167 | 0.60264 |
Vanguard Russell 2000 ETF | 0.03 | 35.648084105685 | 1.48801 |
SPDR S&P Pharmaceuticals ETF | 0.64503 | 29.798803697662 | 1.29889 |
Principal Healthcare Innovators ETF | 0.1058 | 618.4964157054 | 0.8416 |
Future Tech ETF | 0.1058 | 426.33969118983 | 0.8416 |
Supervisor | Cargo | Pagamento | Ano de nascimento |
---|---|---|---|
Mr. Samuel S. Kintz M.B.A. | Co-Founder, CEO, Secretary & Director | 597k | 1986 (38 anos) |
Mr. Benjamin Hohl | CFO & Head of Corporate Development | 488.5k | 1990 (34 ano) |
Dr. Helen Louise Collins M.D. | Chief Medical Officer | 558k | 1963 (61 ano) |
Dr. Joseph P. Lyssikatos Ph.D. | Co-Founder & Chief Scientific Officer | N/A | 1965 (59 anos) |
Mr. Anish Patel Pharm.D. | Co-Founder & COO | N/A | 1981 (43 ano) |
Dr. Galya D. Blachman Esq., Ph.D. | Chief Legal Officer & Head of Business Development | N/A | 1977 (47 anos) |
Site: https://www.enliventherapeutics.com